Search Results - "Nielsen, Lasse Lykke"

  • Showing 1 - 2 results of 2
Refine Results
  1. 1
    Effect of once‐weekly semaglutide versus thrice‐daily insulin aspart, both as add‐on to metformin and optimized insulin glargine treatment in participants with type 2 diabetes (SUSTAIN 11): A randomized, open‐label, multinational, phase 3b trial

    Effect of once‐weekly semaglutide versus thrice‐daily insulin aspart, both as add‐on to metformin and optimized insulin glargine treatment in participants with type 2 diabetes (SUSTAIN 11): A randomized, open‐label, multinational, phase 3b trial by Kellerer, Monika, Kaltoft, Margit Staum, Lawson, Jack, Nielsen, Lasse Lykke, Strojek, Krzysztof, Tabak, Ömür, Jacob, Stephan

    Published in Diabetes, obesity & metabolism (01-09-2022)
    “…Aim To compare the efficacy and safety of once‐weekly (OW) semaglutide versus thrice‐daily (TID) insulin aspart (IAsp) in participants with inadequately…”
    Get full text
    Journal Article
    Save to List
    Saved in:
  2. 2
    Pharmacokinetics, Safety and Tolerability of Once-Weekly Subcutaneous Semaglutide in Healthy Chinese Subjects: A Double-Blind, Phase 1, Randomized Controlled Trial

    Pharmacokinetics, Safety and Tolerability of Once-Weekly Subcutaneous Semaglutide in Healthy Chinese Subjects: A Double-Blind, Phase 1, Randomized Controlled Trial by Shi, Aixin, Xie, Panpan, Nielsen, Lasse Lykke, Skjøth, Trine Vang, He, Xuemei, Haugaard, Sine Pfeiffer

    Published in Advances in therapy (01-01-2021)
    “…Introduction Once-weekly (OW) subcutaneous (s.c.) semaglutide is an injectable glucagon-like peptide-1 (GLP-1) analogue approved for the treatment of type 2…”
    Get full text
    Journal Article
    Save to List
    Saved in:

Search Tools: